申请人:Sanwa Kagaku Kenkyyusho Co., Ltd.
公开号:US05001240A1
公开(公告)日:1991-03-19
Hydantoin derivatives and salts thereof, intermediates therefor, process for the preparation thereof, and medicines containing the derivatives, wherein said derivatives have the formula ##STR1## wherein one of V and W is hydrogen and the other is a halogenomethyl group, 1H-tetrazol-5-yl radical, --COOR group, in which R is hydrogen atom, an alkyl group, --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n is an integer of 1 to 113) or substituted phenyl, ##STR2## group, in which R.sub.1 and R.sub.2 are same or different independently, each is hydrogen atom, an alkyl group, substituted phenyl or --(CH.sub.2 CH.sub.2 O)nCH.sub.3 group (n has the meaning as referred to) or R.sub.1 may form a heterocyclic ring together with R.sub.2 and nitrogen or oxygen atom, --CH.sub.2 OR.sub.3 group or ##STR3## group, in which R.sub.3 and R.sub.4 are same or different independently and each is hydrogen atom or an alkyl group, X is oxygen or sulfur atom, and Y and Z are same or different independently and each is hydrogen atom, a halogen atom, alkyl group, alkoxy group, alkylmercapto group, nitro radical or --NHR.sub.5 group, in which R.sub.5 is hydrogen atom or an acyl group. The derivatives and salts thereof are useful for the treatment of complications of diabetes.
含肟类衍生物及其盐、其中间体、其制备方法和含有该衍生物的药物,其中所述衍生物具有以下式子:##STR1## 其中V和W中的一个为氢,另一个为卤代甲基基团、1H-四唑-5-基基团、--COOR基团,其中R为氢原子、烷基、--(CH.sub.2 CH.sub.2 O)nCH.sub.3基团(n为1至113的整数)或取代苯基,##STR2##基团,其中R.sub.1和R.sub.2各自独立地相同或不同,每个为氢原子、烷基、取代苯基或--(CH.sub.2 CH.sub.2 O)nCH.sub.3基团(n的含义如上所述),或R.sub.1可以与R.sub.2和氮或氧原子一起形成杂环环,--CH.sub.2 OR.sub.3基团或##STR3##基团,其中R.sub.3和R.sub.4各自独立地相同或不同,每个为氢原子或烷基,X为氧或硫原子,Y和Z各自独立地相同或不同,每个为氢原子、卤原子、烷基、烷氧基、烷基硫基、硝基基团或--NHR.sub.5基团,其中R.sub.5为氢原子或酰基。该衍生物及其盐对糖尿病并发症的治疗有用。